--- title: "Your Series B Will Stall Without an IP Portfolio. Here Is the Proof." slug: ip-portfolio-series-b-fundraising date: 2026-04-04 url: https://beyondelevation.com/blog/post.html?slug=ip-portfolio-series-b-fundraising author: Hayat Amin site: Beyond Elevation --- # Your Series B Will Stall Without an IP Portfolio. Here Is the Proof. Sixty-one percent of Series B deals that stall do so because of IP weakness uncovered in due diligence. Not product problems. Not revenue shortfalls. Intellectual property. That number should terrify every founder who has spent two years building a product and zero hours building an IP portfolio. Because here is what actually happens at Series B: the cheque size gets larger, the due diligence gets deeper, and the investors start asking questions your seed-round backers never did. Questions like: What do you own that a well-funded competitor cannot replicate in 18 months? Where are the granted patents? What is your freedom-to-operate position? How is your proprietary data structured, documented, and legally protected? If your answer to any of these is a blank stare, your round is dead. Not because the product is bad. Because the risk is unpriced. ## Why Series B Is Where IP Becomes Non-Negotiable At seed and Series A, investors bet on founders and markets. They tolerate IP gaps because the company is still finding product-market fit. The assumption is that protection will come later. Series B is "later." At this stage, the company has revenue, customers, and a proven model. The investor is no longer betting on potential — they are pricing a business. And businesses get priced on defensibility. Companies with patent portfolios are 10.2x more likely to secure early-stage funding according to published research. By Series B, that multiplier is not a nice-to-have. It is a gate. The reason is simple maths. A Series B cheque is typically $15M to $50M. At that commitment level, investors model downside scenarios obsessively. An unprotected technology stack is a downside scenario. A competitor filing patents that overlap your core product is a downside scenario. A key engineer leaving with undocumented trade secrets is a downside scenario. Every one of these risks gets priced — or the deal does not close. ## What Series B Investors Actually Look For in Your IP **Granted patents or credible pending applications.** Provisional filings are a start. But by Series B, investors expect to see at least two to five patent applications progressing through prosecution, ideally with one or more granted. The claims should cover your core differentiators — the specific technical innovations that make your product commercially superior. Vanity patents on trivial features do not move the needle. Patents on your proprietary inference pipeline, your data processing architecture, or your novel training methodology do. **Freedom-to-operate analysis.** This is the question founders consistently underestimate. It is not enough to own patents. You need evidence that your product does not infringe someone else's patents. A formal FTO analysis — conducted by qualified patent counsel — maps your product's functionality against the existing patent landscape and identifies potential risks before an investor's lawyers do. Discovering an FTO problem during due diligence is a round-killer. Discovering it beforehand and having a documented mitigation strategy is a sign of operational maturity. **Clean IP ownership chain.** Every line of code, every algorithm, every dataset must be unambiguously assigned to the company. Not to a founder's personal LLC. Not to a contractor who never signed an IP assignment agreement. Not to a university where the CTO did their PhD. Beyond Elevation has seen eight-figure deals collapse over a single missing contractor assignment. One document. Eight figures. That is not an exaggeration — it is a pattern. **Documented trade secrets programme.** If your competitive advantage includes proprietary processes, training recipes, or domain-specific know-how, those assets need formal documentation, access controls, and confidentiality agreements. "It is all in our engineers' heads" is not a trade secret — it is a liability. Investors want to see that institutional knowledge is captured, classified, and legally protected. ## The IP Portfolio That Gets a Series B Done Here is the minimum viable IP portfolio that Beyond Elevation recommends for Series B readiness. This is not aspirational. This is the baseline that separates funded companies from stalled ones. **Three to five patent filings covering core technology.** Focus on the innovations that create the widest competitive distance. File provisionals early, convert to full utility applications, and push prosecution aggressively before your fundraise timeline. Each filing should map directly to a product capability that drives revenue or retention. **A completed IP audit.** Document every protectable innovation in your stack. Categorise each as patent, trade secret, copyright, or trademark. Identify gaps. Build a filing roadmap that aligns with your product roadmap and fundraise timeline. This audit typically takes two to four weeks with experienced counsel and pays for itself many times over in valuation impact. **An IP register.** A single document listing every IP asset, its status, its jurisdiction, its maintenance schedule, and its commercial relevance. This is the first document a diligence team requests. If you do not have it, you look unprepared. If you do, you look like a company that takes defensibility seriously. **Clean assignment agreements.** Every founder, employee, and contractor who has contributed to the technology must have a signed IP assignment on file. No exceptions. Audit this before the fundraise, not during it. **Freedom-to-operate clearance.** At minimum, a landscape analysis covering the patent families most relevant to your core product. At best, a formal FTO opinion from qualified counsel that you can share with investors under NDA. ## How IP Directly Impacts Your Series B Valuation This is not abstract. The numbers are specific. Position Imaging came to Beyond Elevation with 66 patents that needed restructuring. After a strategic IP reorganisation, those patents became licensable, enforceable, and directly tied to commercial revenue streams. The portfolio went from a cost centre to a value driver — the kind of transformation that moves valuations by multiples, not percentages. DGS engaged Beyond Elevation for data monetisation strategy. The result: a structured framework for turning proprietary data into a licensable asset with recurring revenue potential. Their CEO, Fernando Murias, described it as fundamentally changing how they think about their business value. These are not edge cases. Companies with structured IP portfolios consistently command 30 to 60 percent higher valuations in fundraising and M&A. At a $40M Series B valuation, that premium represents $12M to $24M in additional enterprise value — created not by building new product, but by properly structuring and protecting the innovations that already exist. ## The 90-Day Series B IP Readiness Plan **Days 1–14:** Complete an IP audit. Map every innovation. Identify ownership gaps. Prioritise filing candidates. **Days 15–45:** File provisional patent applications on three to five core innovations. Begin FTO landscape analysis. Audit and remediate assignment agreements. **Days 46–75:** Document trade secrets formally. Build IP register. Structure data asset documentation and provenance records. **Days 76–90:** Compile diligence-ready IP package. Brief your fundraise counsel. Integrate IP narrative into investor materials. Ninety days. That is the difference between a Series B that closes at a premium and one that stalls in diligence. The work is not complex. It just requires discipline and experienced guidance. ## FAQ: IP Portfolio for Series B Fundraising ### How many patents does a startup need for a Series B round? A startup typically needs three to five patent filings — a mix of granted patents and credible pending applications — covering its core technical differentiators to satisfy Series B due diligence. The focus should be on quality and relevance to revenue-driving capabilities, not volume. Beyond Elevation helps founders identify and prioritise the specific innovations that create the most competitive distance and investor confidence. ### What is freedom-to-operate and why do Series B investors require it? Freedom-to-operate is a legal analysis confirming that your product does not infringe existing patents held by competitors or other rights holders. Series B investors require it because patent infringement lawsuits can cost millions and force product redesigns. An FTO analysis identifies these risks before they become deal-breakers. Beyond Elevation structures FTO assessments as part of comprehensive Series B IP readiness packages. ### Can you raise a Series B without any patents? It is possible but increasingly difficult, especially in AI and deep tech. Without patents, investors see unmitigated competitive risk — any well-funded competitor can replicate your technology without legal consequence. Companies that raise Series B without patents typically accept significantly lower valuations and more restrictive terms. The cost of filing three to five provisional patents before your round is a fraction of the valuation discount you will absorb without them. ### How does Beyond Elevation prepare companies for Series B IP due diligence? Beyond Elevation runs a structured 90-day readiness programme that includes IP audits, patent filing strategy, freedom-to-operate analysis, trade secret documentation, assignment remediation, and diligence package preparation. The goal is a complete, investor-ready IP position that withstands scrutiny and commands a valuation premium. Book a strategy session at [beyondelevation.com](https://beyondelevation.com) to start your Series B IP preparation. --- *Published on [Beyond Elevation](https://beyondelevation.com) — IP Strategy & Licensing Revenue Consultancy*